BlueStar

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

Open

Prior lines

1, 2

Histology

Endometrioid, Mucinous Serous Clear-cell Carcinocarcoma Other (bv. mixed/rare)

Phase

I/II

Treatment

All participants in this trial will receive AZD8205.
No randomization will be performed.

Treatment duration

The treatment with AZD8205 can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.